What is the address of MEDIPSY?

The registered office of MEDIPSY is located at Rue de la Haie 23, 7190 Ecaussinnes.

Is MEDIPSY still active?

Yes. According to the CBE (30 October 2026) MEDIPSY is active, legal situation “Normale toestand”, started on 4 December 1991.

Is MEDIPSY registered on Peppol?

No, MEDIPSY is currently not registered on the Peppol network.

What is the enterprise number of MEDIPSY?

The enterprise number of MEDIPSY is BE0445947897.

When was MEDIPSY founded?

MEDIPSY was founded on 4 December 1991.

Who are the directors of MEDIPSY?

According to the 2025 annual accounts, the directors of MEDIPSY are: ETIENNE VAN HONACKER, NINA VAN HONACKER.

Is MEDIPSY a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 December 1991; 6 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did MEDIPSY make in 2025?

MEDIPSY recorded a loss after taxes of € 43,769 in financial year 2025.

What is the revenue of MEDIPSY?

As a small company, MEDIPSY is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -13,861.

MEDIPSY (Private Limited) - Ecaussinnes - BE0445947897

Dossier MEDIPSY, printed on 30 October 2026 from databakkes.be/en/0445947897/medipsy. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Figures corrected NBB

Corrected annual account filed for 2022.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

MEDIPSY from Ecaussinnes, company number BE0445947897, closed financial year 2025 with a result of € -43,769 after tax. For that financial year MEDIPSY recorded a gross margin of € -13,861 and equity of € 238,530. Compared with financial year 2024, the result moved from € -14,767 to € -43,769. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 5, 2026.

What it is worth Healthy

€ 238,530

▼ 16% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -43,769

▼ 196 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 68,930

▼ 59% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 182,730.

People and assets in 2025

Vehicles and equipment

€ 44,693

▲ 10% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 7,182

▲ € 5,852 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 1,431

▼ 96% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 412,045 Gross margin 2022: € 412,045 First fiscal year in the series	€ 24,339 Gross margin 2023: € 24,339 ▼ 94% vs 2022 (€ 412,045) Unfavourable step	€ 20,362 Gross margin 2024: € 20,362 ▼ 16% vs 2023 (€ 24,339) Unfavourable step	€ -13,861 Gross margin 2025: € -13,861 ▼ € 34,224 vs 2024 (€ 20,362) Unfavourable step	▼ € 34,224
Profit after taxes	€ 293,144 Profit after taxes 2022: € 293,144 First fiscal year in the series	€ 1,585 Profit after taxes 2023: € 1,585 ▼ 99% vs 2022 (€ 293,144) Unfavourable step	€ -14,767 Profit after taxes 2024: € -14,767 ▼ € 16,352 vs 2023 (€ 1,585) Unfavourable step	€ -43,769 Profit after taxes 2025: € -43,769 ▼ € 29,002 vs 2024 (€ -14,767) Unfavourable step	▼ € 29,002
Equity	€ 665,723 Equity 2022: € 665,723 First fiscal year in the series	€ 297,067 Equity 2023: € 297,067 ▼ 55% vs 2022 (€ 665,723) Unfavourable step	€ 282,300 Equity 2024: € 282,300 ▼ 5% vs 2023 (€ 297,067) Unfavourable step	€ 238,530 Equity 2025: € 238,530 ▼ 16% vs 2024 (€ 282,300) Unfavourable step	▼ 16%
Total debts	€ 133,487 Total debts 2022: € 133,487 First fiscal year in the series	€ 113,348 Total debts 2023: € 113,348 ▼ 15% vs 2022 (€ 133,487) Favourable step	€ 38,974 Total debts 2024: € 38,974 ▼ 66% vs 2023 (€ 113,348) Favourable step	€ 13,272 Total debts 2025: € 13,272 ▼ 66% vs 2024 (€ 38,974) Favourable step	▼ 66%
Cash	€ 656,672 Cash 2022: € 656,672 First fiscal year in the series	€ 155,931 Cash 2023: € 155,931 ▼ 76% vs 2022 (€ 656,672) Unfavourable step	€ 168,412 Cash 2024: € 168,412 ▲ 8% vs 2023 (€ 155,931) Favourable step	€ 68,930 Cash 2025: € 68,930 ▼ 59% vs 2024 (€ 168,412) Unfavourable step	▼ 59%
Land & buildings	€ 26,412 Land & buildings 2022: € 26,412 First fiscal year in the series	€ 23,771 Land & buildings 2023: € 23,771 ▼ 10% vs 2022 (€ 26,412) Unchanged	€ 21,130 Land & buildings 2024: € 21,130 ▼ 11% vs 2023 (€ 23,771) Unchanged	€ 18,490 Land & buildings 2025: € 18,490 ▼ 12% vs 2024 (€ 21,130) Unchanged	▼ 12%
Retained profit	€ 639,683 Retained profit 2022: € 639,683 First fiscal year in the series	€ 241,267 Retained profit 2023: € 241,267 ▼ 62% vs 2022 (€ 639,683) Unfavourable step	€ 226,500 Retained profit 2024: € 226,500 ▼ 6% vs 2023 (€ 241,267) Unfavourable step	€ 182,730 Retained profit 2025: € 182,730 ▼ 19% vs 2024 (€ 226,500) Unfavourable step	▼ 19%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 400,000 Dividend 2023: € 400,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 400,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 799,209 Balance sheet total 2022: € 799,209 First fiscal year in the series	€ 410,415 Balance sheet total 2023: € 410,415 ▼ 49% vs 2022 (€ 799,209) Unchanged	€ 321,274 Balance sheet total 2024: € 321,274 ▼ 22% vs 2023 (€ 410,415) Unchanged	€ 251,803 Balance sheet total 2025: € 251,803 ▼ 22% vs 2024 (€ 321,274) Unchanged	▼ 22%

Key figures of MEDIPSY, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MEDIPSY?

What happened at MEDIPSY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 5, 2026 New annual accounts for financial year 2025: loss of € 43,769. filed late Source: NBB ↗
Dec 4, 1991 New establishment in Ecaussinnes. KBO
Dec 4, 1991 Start of the company according to the CBE. KBO

In short

From € 293,144 profit in 2022 to € 43,769 loss in 2025.

Paid € 106,365 in corporate taxes since 2022.

Best year ever: 2022, with € 293,144 profit.

Paid out € 400,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

ETIENNE VAN HONACKER

NINA VAN HONACKER

MEDIPSY

DOCTAR (En liquidation) 100%

Behind MEDIPSY are ETIENNE VAN HONACKER and NINA VAN HONACKER. It owns 100% of DOCTAR (En liquidation) itself.

Directors

According to the 2025 annual accounts

ETIENNE VAN HONACKER

Director

NINA VAN HONACKER

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de la Haie 23

7190 Ecaussinnes

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0445.947.897
VAT number: BE 0445.947.897
Registered office: Rue de la Haie 23, 7190 Ecaussinnes
Names & denominations: MEDIPSY
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 4 December 1991
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗